布地格福与布地奈德福莫特罗治疗哮喘合并慢阻肺患者的疗效对比OA

Objective:To investigate the efficacy of budesonide/glycopyrronium bromide/formoterol fumarate and budesonide/formoterol in treating patients with asthma complicated with chronic obstructive pulmonary disease(COPD).Meth-ods:A total of 86 patients with asthma and COPD were selected and divided into group A and B according to different treatment methods,with 43 cases in each group.Patients in group A were treated with budesonide/formoterol,while those in group B were treated with budesonide/glycopyrronium bromide/formoterol fumarate,both groups were treated for 3 months.The clini-cal efficacy,lung function[forced expiratory volume in one second(FEV1),peak expiratory flow(PEF),FEV1/forced vital ca-pacity ratio(FEV1/FVC)],blood gas indicators[arterial partial pressure of carbon dioxide(PaCO2),arterial partial pressure of oxygen(PaO2),and arterial oxygen saturation(SaO2)],inflammatory indicators[high-sensitivity C-reactive protein(hs-CRP),interleukin17(IL-17),matrix metalloproteinase-9(MMP-9)levels],biochemical indicators[fractional exhaled nitric ox-ide(FeNO)and total immunoglobulin E(IgE)levels],and incidence of adverse reactions were compared between the two groups.Results:The total effective rate,FEV1,PaO2,FEV1/FVC,and SaO2,in group B were higher than those in group A,while PEF,hs-CRP,PaCO2,IL-17,MMP-9,FeNO,and total IgE levels were lower than those in group A(P＜0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion:Compared with budesonide/formoterol,budesonide/glycopyrronium bromide/formoterol fumarate is more effective in treating asthma complicated with COPD.It can help improve pulmonary function,regulate FeNO and IgE levels,and relieve inflammatory response,with good safety.